CN117138104A - Antioxidant protein peptide-based nano hydrogel for burn wound surface - Google Patents
Antioxidant protein peptide-based nano hydrogel for burn wound surface Download PDFInfo
- Publication number
- CN117138104A CN117138104A CN202311198710.5A CN202311198710A CN117138104A CN 117138104 A CN117138104 A CN 117138104A CN 202311198710 A CN202311198710 A CN 202311198710A CN 117138104 A CN117138104 A CN 117138104A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- senps
- protein peptide
- reaction
- network
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 38
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 15
- 239000002105 nanoparticle Substances 0.000 claims abstract description 69
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims abstract description 31
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 29
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 29
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 29
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 claims abstract description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 21
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004327 boric acid Substances 0.000 claims abstract description 19
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 18
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 18
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 18
- 239000006087 Silane Coupling Agent Substances 0.000 claims abstract description 15
- 230000004048 modification Effects 0.000 claims abstract description 15
- 238000012986 modification Methods 0.000 claims abstract description 15
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 12
- 239000011669 selenium Substances 0.000 claims abstract description 12
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 239000000499 gel Substances 0.000 claims abstract description 5
- 239000007853 buffer solution Substances 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 238000003756 stirring Methods 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 7
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract 1
- 125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 abstract 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 48
- 208000027418 Wounds and injury Diseases 0.000 description 21
- 206010052428 Wound Diseases 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 18
- 235000010269 sulphur dioxide Nutrition 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004291 sulphur dioxide Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2329/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2329/02—Homopolymers or copolymers of unsaturated alcohols
- C08J2329/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2429/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2429/02—Homopolymers or copolymers of unsaturated alcohols
- C08J2429/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2489/00—Characterised by the use of proteins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an antioxidant protein peptide-based nano hydrogel for burn wound, which relates to the technical field of burn hydrogel, and adopts the technical scheme that selenium nano particles (Sepps) are subjected to covalent modification in acetic acid buffer solution, and are further activated by using a silane coupling agent, the modified Sepps and protein peptide are coupled through EDC and Sulfo-NHS, the compound is mixed with Hyaluronic Acid (HA), and is subjected to first network crosslinking through sulfur dioxide, PVA and boric acid are added to form a second network, and Tween 20 is added as an auxiliary agent to improve gel performance, and the invention HAs the beneficial effects that: the invention improves the dispersibility and mechanical strength of the hydrogel through covalent modification and double-network structure of the selenium nano particles (Senps). The protein peptide-nanoparticle composite increases biocompatibility and antioxidation effect, and is helpful for burn healing.
Description
Technical Field
The invention relates to the technical field of burn hydrogels, in particular to an antioxidant protein peptide-based nano-hydrogel for burn wounds.
Background
Burns are a common severe wound, and their treatment not only requires wound healing, but also requires antioxidant treatment of the wound to reduce inflammation and other complications. Hydrogels are well known for their good biocompatibility, wettability and breathability to find widespread use in wound therapy, and in particular, they provide a sustained moist environment for the wound surface, thereby promoting wound healing. However, how to introduce oxidation resistance into these hydrogels to further improve the therapeutic effect on burn wounds has become a hot spot of current research.
In order to provide sustained antioxidant protection to burn wounds, methods have been known in the art to incorporate antioxidant nanoparticles such as selenium nanoparticles (SeNPs) into hydrogels. However, these nanoparticles tend to deposit or aggregate easily in the gel, resulting in uneven release thereof, reducing the therapeutic effect. In addition, the prior art often suffers from the problems of poor compatibility among materials, poor crosslinking effect and the like when preparing the antioxidant protein peptide-based nano hydrogel, so that the stability, the antioxidant property and the biocompatibility of the gel are difficult to be fully ensured.
In view of the above, the present invention aims to provide a novel antioxidant protein peptide-based nano-hydrogel for burn wound and a preparation method thereof, which are expected to solve the problem of dispersibility of nanoparticles in the hydrogel and to improve the crosslinking effect and compatibility of the gel. In addition, it is desirable to optimize the preparation conditions so that the resulting hydrogels have more durable, uniform antioxidant release characteristics, thereby more effectively promoting healing of burn wounds.
Disclosure of Invention
In order to achieve the above object, the present invention provides an antioxidant protein peptide-based nano hydrogel for burn wound, which comprises the following steps:
a) Covalent modification of selenium nanoparticles (SeNPs):
putting Senps into acetic acid buffer solution, stirring until the SeNPs are completely dispersed, adding silane coupling agent, continuously stirring, separating modified nano particles by using a centrifuge after the reaction is completed, washing the nano particles by using deionized water, and finally suspending the nano particles in the deionized water;
b) Linking the nanoparticle to the protein peptide:
uniformly mixing 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (Sulfo-NHS) with modified Senps, gradually adding protein peptide, continuously stirring the mixture, and centrifuging after the reaction is finished to obtain a protein peptide-nanoparticle compound;
c) Forming a first network:
uniformly mixing the hyaluronic acid solution and the protein peptide-nanoparticle compound, gradually adding sulfur dioxide, and stirring for reaction;
d) Forming a second network:
adding boric acid solution into the mixture of c), and continuously stirring for reaction;
e) And (3) introducing an auxiliary agent:
tween 20 was added to the reaction product of d) to obtain a hydrogel.
Preferably, in step a), the silane coupling agent is used in an amount of 5-10% by weight of the nanoparticles. Preferably, the particle size of the SeNPs in step a) is from 10 to 50 nm;
preferably, in step a), the acetate buffer concentration is 0.1-0.5mg/ml;
preferably, in step a) the pH of the acetate buffer used is in the range of 4.5-6.0;
preferably, in step a), stirring is continued and the reaction is carried out for 2-4 hours;
preferably, in step b), EDC: sulfo-NHS: the molar ratio of the SeNPs is (0.5-2): (8-12).
Preferably, the amount of protein peptide added in step b) is 2-5% by weight of SeNPs.
Preferably, in step b), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (Sulfo-NHS) and the modified SenPS are mixed homogeneously and stirred continuously for 10-20 minutes to activate EDC and Sulfo-NHS;
preferably, in step b), the protein peptide is gradually added, the pH is adjusted to 7-8, and the mixture is continuously stirred for 4-6 hours;
preferably, the concentration of hyaluronic acid in step c) is in the range of 0.5-3% (w/v).
Preferably, the sulfur dioxide used in step c) is added in an amount of 1-5% by weight of hyaluronic acid.
Preferably, the stirred reaction of step C) is carried out at 25-40 ℃.
Preferably, in step c) sulfur dioxide is gradually added, stirring is continued and the mixture is allowed to react for 2-4 hours at a pH of about 7;
preferably, in step d), a PVA solution having a molecular weight of 30,000-90,000,5-10% (w/v) is selected and stirred at 25℃for 30 minutes;
preferably, in step d), the concentration of the boric acid solution is in the range of 0.3-3% (w/v);
preferably, in step d), the pH of the mixture is adjusted to a range of 8-9 and the reaction is continued with stirring at a temperature of 37℃for 4-6 hours;
preferably, tween 20 is used in an amount of 0.1-1% of the total weight of the hydrogel in step e);
preferably, tween 20 is selected in an amount of 0.01-0.1% (v/v);
preferably, in step e), the resulting hydrogel is cooled at 4 ℃ for 12 hours and then left at room temperature for at least 24 hours to ensure complete crosslinking.
a) Covalent modification of selenium nanoparticles (SeNPs):
the chemical modification of the SeNPs is realized by utilizing the surface reaction of the silane coupling agent and the SeNPs, and the step ensures that the surface of the SeNPs is modified, thereby creating conditions for the subsequent combination with protein peptides.
The specific particle size of the SeNPs, the concentration of the acetic acid buffer solution and the pH range ensure the optimal reaction of the silane coupling agent and the SeNPs, realize more uniform and stable modification of the SeNPs and provide a more stable nano-base for the subsequent steps.
Naked SeNPs are easily oxidized or reacted with other substances in the environment, so that the structural and functional properties of the naked SeNPs are changed, and a protective layer can be provided for the naked SeNPs through modification, so that the stability of the naked SeNPs is improved; in order to ensure compatibility of SeNPs with biological systems, surface modification is required; the surface charge of SeNPs can affect its dispersibility in liquids, and the modification can optimize its dispersibility, thereby improving its uniform distribution in hydrogels.
b) Linking the nanoparticle to the protein peptide:
EDC and Sulfo-NHS can activate the surface carboxyl group of the SENPs, form an amide bond with amino groups in the protein peptide, form stable combination of the protein peptide and the SENPs, and increase the biological activity of the nano particles.
Activation of carboxyl groups on the surface of SeNPs can be maximized by selecting the specific molar ratios of EDC, sulfo-NHS and SeNPs. In addition, by controlling the addition amount of the protein peptide and the reaction pH, the maximum binding efficiency of the protein peptide and the Senps can be ensured, a more stable and high-density protein peptide-nanoparticle complex is formed, and higher bioactivity and oxidation resistance are ensured.
c) Forming a first network:
sulfur dioxide reacts with hyaluronic acid to cause cross-linking of the hyaluronic acid to form a network structure; ensures the structural stability of the hydrogel and increases the adhesiveness to burn wound surfaces.
By selecting specific concentrations of hyaluronic acid and sulfur dioxide, and controlling the reaction temperature and pH, optimal cross-linking of hyaluronic acid can be ensured, forming a first network structure with high elasticity and stability, providing a solid basis for the subsequent steps.
d) Forming a second network:
the boric acid reacts with PVA to form a stable boric acid-polyol complex, so that the net structure is further enhanced, the mechanical strength of the hydrogel is further enhanced, and the sufficient supporting effect on the burn wound surface is ensured.
By selecting PVA and boric acid of specific molecular weight and concentration, and controlling the reaction temperature and pH, the crosslinking between boric acid and PVA can be maximized, a stable second network structure is formed, and the mechanical strength and stability of the hydrogel are further enhanced.
First a first network is formed in which the protein peptide is immobilized and protected, ensuring its stability and functionality. Thus, the protein peptide is not affected by possible adverse reaction conditions when the formation of the second network is performed, the first network being responsible for providing the biological activity, while the second network is more concerned with the physical properties; thus, each network has a definite purpose, rather than a mix of the two, possibly sacrificing certain characteristics; by sequentially forming the two networks, the respective preparation conditions can be optimized respectively, the process is simplified, and the complexity possibly brought by adding all the components simultaneously is avoided.
e) And (3) introducing an auxiliary agent:
tween 20 is used as a nonionic surfactant and uniformly dispersed in the hydrogel, so that the fluidity of the hydrogel is improved, the lubricity of the hydrogel is increased, the hydrogel is easier to smear on burn wounds, meanwhile, the wound can be kept moist, the wound healing is accelerated, the Tween 20 with specific concentration is selected, the Tween 20 is uniformly distributed in the hydrogel, the lubricity and the adhesiveness of the hydrogel are increased, and the hydrogel is easier to smear and uniformly cover the burn wounds.
The technical scheme provided by the embodiment of the invention has the beneficial effects that:
improving the dispersibility of the nano particles: through covalent modification of selenium nanoparticles (SeNPs), the dispersibility of the nanoparticles in the hydrogel is remarkably improved, and the deposition and aggregation of the nanoparticles are effectively prevented. This ensures a uniform distribution of nanoparticles in the hydrogel, providing a sustained and uniform antioxidant protection for the burn wound.
Enhancing the crosslinking effect: by utilizing the crosslinking reaction of hyaluronic acid and sulfur dioxide and combining the interaction of boric acid and PVA, a stable and uniform dual-network structure is formed. This not only enhances the mechanical strength of the hydrogel, but also greatly improves its stability.
Optimizing biocompatibility: the formation of the protein peptide-nanoparticle complex ensures the stable existence of the protein peptide and improves the biocompatibility of the whole hydrogel. This means that the hydrogel is not easy to cause adverse reaction when in use, and is more beneficial to healing of burn wound surfaces.
Durable and uniform antioxidant release: in combination with the modification of the nanoparticles and the optimized crosslinking technique, the invention ensures the sustained release of selenium nanoparticles in hydrogels. The burn wound surface is provided with continuous and uniform antioxidation protection, is helpful for reducing oxidative stress injury and accelerating wound healing.
And (3) optimizing preparation conditions: the invention considers the optimal conditions of each raw material and each step, thereby ensuring that the prepared hydrogel reaches an optimal state in physical, chemical and biological properties, and simultaneously ensuring the economical efficiency and the practicability of the hydrogel in production and practical application.
Comprehensively solve multiple problems: the invention comprehensively considers the dispersibility, the crosslinking effect, the compatibility and the antioxidation release characteristics of the nano particles, and provides a comprehensive and efficient solution for burn wound treatment.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. Of course, the specific embodiments described herein are for purposes of illustration only and are not intended to limit the invention.
Example 1
Covalent modification of selenium nanoparticles (SeNPs):
senps with a particle size of 30 nm were placed in 0.3mg/ml acetic acid buffer at pH 5.0.
After stirring to complete dispersion, a silane coupling agent was added, corresponding to 7.5% by weight of the nanoparticles.
The reaction was stirred at room temperature for 3 hours.
And separating the modified nano particles by using a centrifugal machine, and washing the nano particles with deionized water until the nano particles are clean.
Finally, the nano particles are suspended in deionized water for standby.
Linking the nanoparticle to the protein peptide:
mixing EDC, sulfo-NHS with modified Senps, wherein EDC: sulfo-NHS: the molar ratio of Senps was 1:1:10.
Stirring was uniform and continued for 15 minutes to activate EDC and Sulfo-NHS.
The protein peptide was gradually added in an amount of 3.5% by weight relative to the weight of SeNPs.
The pH was adjusted to 7.5 and the mixture was stirred for 5 hours.
And obtaining the protein peptide-nanoparticle complex by centrifugation.
Forming a first network:
a hyaluronic acid solution with a concentration of 2% (w/v) was mixed with the protein peptide-nanoparticle complex uniformly.
At 30 ℃, sulfur dioxide was gradually added, corresponding to 3% by weight of hyaluronic acid.
At a pH of about 7, stirring was continued and the mixture was allowed to react for 3 hours.
Forming a second network:
a7.5% (w/v) PVA solution having a molecular weight of 60,000 was selected at 25℃and was mixed with the above mixture and stirred for 30 minutes.
A1.5% (w/v) boric acid solution was gradually added.
The pH of the mixture was adjusted to 8.5 and the reaction was continued with stirring at 37℃for 5 hours.
And (3) introducing an auxiliary agent:
to the above reaction was added 0.05% (v/v) Tween 20.
Uniformly mixing to obtain the hydrogel.
The resulting hydrogel was cooled at 4 ℃ for 12 hours and then left at room temperature for 24 hours to ensure complete crosslinking.
Example 2
All other steps according to example 1 are distinguished in that the particle size of the SeNPs in step a) is 10 nm.
Example 3
All other steps according to example 1 are distinguished in that the particle size of the SeNPs in step a) is 50 nm.
Example 4
All other steps according to example 1 are distinguished in that the silane coupling agent is used in step a) in an amount of 5% by weight of the nanoparticles.
Example 5
All other steps according to example 1 are distinguished in that the silane coupling agent is used in step a) in an amount of 10% by weight of the nanoparticles.
Example 6
All other steps according to example 1 are distinguished in that in step b) EDC: sulfo-NHS: the molar ratio of SeNPs was 0.5:0.5:8.
Example 7
All other steps according to example 1 are distinguished in that in step b) EDC: sulfo-NHS: the molar ratio of Senps was 0.5:0.5:12.
Example 8
All other steps according to example 1 are distinguished in that in step b) EDC: sulfo-NHS: the molar ratio of SeNPs was 0.5:0.5:8.
Example 9
All other steps according to example 1 are distinguished in that in step b) EDC: sulfo-NHS: the molar ratio of Senps was 1:1:8.
Example 10
All other steps according to example 1 are distinguished in that in step b) EDC: sulfo-NHS: the molar ratio of Senps was 1:0.5:8.
Example 11
All other steps according to example 1 are distinguished in that in step b) EDC: sulfo-NHS: the molar ratio of SeNPs was 2:2:12.
Example 12
All other steps according to example 1 are distinguished in that the amount of protein peptide added in step b) is 2% by weight of SeNPs.
Example 13
All other steps according to example 1 are distinguished in that the amount of protein peptide added in step b) is 5% by weight of Senps.
Example 14
All other steps according to example 1 are distinguished in that the concentration of hyaluronic acid in step c) is 0.5% (w/v).
Example 15
All other steps according to example 1 are distinguished in that the concentration of hyaluronic acid in step c) is 3% (w/v).
Example 16
All other steps according to example 1 are distinguished in that the amount of sulphur dioxide added in step c) is 1% by weight of hyaluronic acid.
Example 17
All other steps according to example 1 are distinguished in that sulphur dioxide is added in step c) in an amount of 5% by weight of hyaluronic acid.
Example 18
All other steps according to example 1, except that the stirring reaction of step C) was carried out at 25 ℃.
Example 19
All other steps according to example 1, except that the stirring reaction of step C) was carried out at 40 ℃.
Example 20
All other steps according to example 1 are distinguished in that in step d) the concentration of the boric acid solution is 0.3% (w/v).
Example 21
All other steps according to example 1 are distinguished in that in step d) the concentration of the boric acid solution is 3% (w/v).
Example 22
All other steps according to example 1, except that Tween 20 was used in an amount of 0.1% by weight based on the total weight of the hydrogel in step e).
Example 23
All other steps according to example 1, except that Tween 20 was used in an amount of 1% by total weight of the hydrogel in step e).
Example 24
Covalent modification of selenium nanoparticles (SeNPs):
senps with a particle size of 10 nm were placed in 0.1mg/ml acetic acid buffer at pH 4.5.
After stirring to complete dispersion, a silane coupling agent was added in an amount equivalent to 5% by weight of the nanoparticles.
The reaction was stirred at room temperature for 2 hours.
And separating the modified nano particles by using a centrifugal machine, and washing the nano particles with deionized water until the nano particles are clean.
Finally, the nano particles are suspended in deionized water for standby.
Linking the nanoparticle to the protein peptide:
mixing EDC, sulfo-NHS with modified Senps, wherein EDC: sulfo-NHS: the molar ratio of SeNPs was 0.5:0.5:8.
Stirring was uniform and continued for 10 minutes to activate EDC and Sulfo-NHS.
The protein peptide was gradually added in an amount of 2% by weight relative to the Senps.
The pH was adjusted to 7 and the mixture was stirred for 4 hours.
And obtaining the protein peptide-nanoparticle complex by centrifugation.
Forming a first network:
a hyaluronic acid solution with a concentration of 0.5% (w/v) was mixed uniformly with the protein peptide-nanoparticle complex.
At 25 ℃, sulfur dioxide was gradually added in an amount corresponding to 1% by weight of hyaluronic acid.
At a pH of about 7, stirring was continued and the mixture was allowed to react for 3 hours.
Forming a second network:
a5% (w/v) PVA solution having a molecular weight of 30,000 was selected at 25℃and mixed with the above mixture and stirred for 30 minutes.
A solution of boric acid was gradually added at 0.3% (w/v).
The pH of the mixture was adjusted to 8 and the reaction was continued with stirring at 37℃for 4 hours.
And (3) introducing an auxiliary agent:
to the above reaction was added 0.01% (v/v) Tween 20.
Uniformly mixing to obtain the hydrogel.
The resulting hydrogel was cooled at 4 ℃ for 12 hours and then left at room temperature for 24 hours to ensure complete crosslinking.
Example 25
Covalent modification of selenium nanoparticles (SeNPs):
senps with a particle size of 50 nm were placed in 0.5mg/ml acetic acid buffer, pH 6.
After stirring to complete dispersion, a silane coupling agent was added in an amount equivalent to 10% by weight of the nanoparticles.
The reaction was stirred at room temperature for 4 hours.
And separating the modified nano particles by using a centrifugal machine, and washing the nano particles with deionized water until the nano particles are clean.
Finally, the nano particles are suspended in deionized water for standby.
Linking the nanoparticle to the protein peptide:
mixing EDC, sulfo-NHS with modified Senps, wherein EDC: sulfo-NHS: the molar ratio of SeNPs was 2:2:12.
Stirring was uniform and continued for 20 minutes to activate EDC and Sulfo-NHS.
The protein peptide was gradually added in an amount of 5% by weight relative to the Senps.
The pH was adjusted to 8 and the mixture was stirred for 6 hours.
And obtaining the protein peptide-nanoparticle complex by centrifugation.
Forming a first network:
a hyaluronic acid solution with a concentration of 3% (w/v) was mixed uniformly with the protein peptide-nanoparticle complex.
At 40 ℃, sulfur dioxide was gradually added in an amount of 5% by weight relative to the weight of hyaluronic acid.
At a pH of about 7, stirring was continued and the mixture was allowed to react for 4 hours.
Forming a second network:
a10% (w/v) PVA solution having a molecular weight of 90,000 was selected at 25℃and was mixed with the above mixture and stirred for 30 minutes.
A3% (w/v) boric acid solution was gradually added.
The pH of the mixture was adjusted to 9 and the reaction was continued with stirring at 37℃for 6 hours.
And (3) introducing an auxiliary agent:
to the above reaction was added 0.1% (v/v) Tween 20.
Uniformly mixing to obtain the hydrogel.
The resulting hydrogel was cooled at 4 ℃ for 12 hours and then left at room temperature for 24 hours to ensure complete crosslinking.
Comparative example 1
All other steps according to example 1 were followed, except that unmodified SeNPs were used directly without addition of a silane coupling agent.
Comparative example 2
All other steps according to example 1 are distinguished in that the protein peptide is directly added in the step of not linking the nanoparticle to the protein peptide.
Comparative example 3
All other steps according to example 1 were followed, except that PVA and boric acid were not used, and only hyaluronic acid and sulfur dioxide were relied upon to form a network.
Comparative example 4
All other steps according to example 1 are followed, except that Tween 20 is not added in the step of not introducing an auxiliary agent.
Comparative example 5
Commercially available wet burn and scald ointment
1. Viscosity test
Placing the prepared hydrogel sample into a sample cup of a viscometer to ensure complete coverage of the rotor; after the viscometer was turned on and the instrument was left to stabilize, the viscosity values at the set rotational speed were recorded, each sample was measured at least three times, and then the average was taken.
Temperature: 25 ℃ C (room temperature) ensures a constant temperature during the test.
Rotational speed: rotational speed ranges such as 50rpm, 100rpm and 200rpm were selected to evaluate the viscosity change under different shear conditions.
TABLE 1 results of viscosity test
Project | Viscosity (mPas) 50rpm | Viscosity (mPas) 100rpm | Viscosity (mPas) 200rpm |
Example 1 | 212 | 196 | 183 |
Example 4 | 205 | 190 | 177 |
Example 5 | 215 | 199 | 185 |
Example 22 | 210 | 194 | 181 |
Example 23 | 208 | 193 | 180 |
Comparative example 1 | 220 | 204 | 190 |
Comparative example 4 | 214 | 198 | 184 |
Examples 4 and 5 show the relationship between the concentration of the silane coupling agent and the viscosity, indicating that the concentration of the silane coupling agent contributes to better dispersion.
Examples 22 and 23 demonstrate the effect of increasing Tween 20 concentration on viscosity. The viscosity was slightly changed depending on the amount of Tween 20, but similar to example 1.
Comparative example 1 has the highest viscosity, which may mean that unmodified SeNPs aggregate more easily, resulting in poor dispersibility.
Comparative example 4, without the addition of Tween 20, had a slightly higher viscosity than example 1, which may mean slightly less dispersibility.
2. Determination of crosslink Density:
weighing an antioxidant protein peptide-based nano hydrogel sample, and recording the initial weight;
preparing a large volume of deionized water to ensure that the water is fresh and clean;
completely immersing the prepared hydrogel sample into deionized water;
samples were taken at predetermined time intervals and the surface was gently wiped off with a paper towel.
Re-weigh the sample and record the weight at each time point
The water absorption was calculated using the following formula:
water absorption (%) = (Wt-Wo)/wo×100%
W t: the weight of the sample after water absorption; wo: initial weight of sample.
Table 2 experimental data
Examples/comparative examples | Water absorption (%) |
Example 1 | 55.0 |
Example 14 | 66.7 |
Example 15 | 48.3 |
Example 16 | 72.1 |
Example 17 | 57.8 |
Example 18 | 59.0 |
Example 19 | 53.4 |
Example 20 | 64.2.0 |
Example 21 | 49.5 |
Comparative example 3 | 81.9 |
Examples 1, 14, 15 demonstrate that cross-linking of hyaluronic acid and sulfur dioxide forms a first network, the primary function of which is to provide structural stability and adhesion; high concentration of hyaluronic acid results in high degree of crosslinking, low water absorption, and low concentration of hyaluronic acid results in low degree of crosslinking, high water absorption.
Examples 1, 20, 21, comparative example 3 demonstrate that crosslinking of boric acid and PVA forms a second network, providing mainly mechanical strength. Small changes in boric acid concentration may not significantly affect water absorption because the second network affects mainly mechanical strength rather than water absorption properties; comparative example 3 shows a water absorption of 81.9%, which is the highest among all samples. This is because PVA and boric acid are not used, resulting in the lowest degree of crosslinking. While this provides it with excellent water absorption properties, doing so may compromise the structural stability and mechanical strength of the hydrogel, such high water absorption also means that the hydrogel is not sufficiently stable, especially in situations requiring long-term or high-strength applications. Meanwhile, the lack of PVA and boric acid means that this comparative example lacks a second network structure, which is generally used to increase mechanical strength and stability. The dual network system of the embodiments provides adhesion and structural stability through the first network and mechanical strength through the second network, comprehensively optimizing the performance of the hydrogel. This staged optimization strategy simplifies the manufacturing process and potentially reduces the mutual interference between ingredients, allowing finer control of the properties.
3. Antioxidant Activity test
DPPH (2, 2-diphenyl-1-pyridinehydrazine) radical scavenging test and ABTS (2, 2' -diaminobis (3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging test were used. The following are the detailed steps of the experiment:
DPPH radical scavenging test
Preparing a DPPH solution of 0.1. 0.1 mM using ethanol as a solvent;
the hydrogel sample and DPPH solution were mixed, left to stand in the dark for 20-30 minutes, and absorbance was measured using a spectrophotometer at 517 nm.
The DPPH radical scavenging rate was calculated.
ABTS free radical scavenging assay
Abts+ solution was prepared, the hydrogel sample and abts+ solution were mixed using water as a solvent, left to stand for 6 minutes, and absorbance was measured using a spectrophotometer at 734 nm.
The clearance of ABTS free radicals was calculated.
TABLE 3 experimental data
Test item | DPPH clearance (%) | ABTS clearance (%) |
Example 1 | 95 | 93 |
Example 2 | 78 | 82 |
Example 3 | 81 | 76 |
Example 6 | 68 | 71 |
Example 7 | 72 | 65 |
Example 8 | 77 | 70 |
Example 9 | 79 | 80 |
Example 10 | 67 | 74 |
Example 11 | 83 | 85 |
Example 12 | 74 | 72 |
Example 13 | 89 | 88 |
Comparative example 2 | 50 | 54 |
Comparative example 5 | 45 | 48 |
Example 1 used 30 nm selenium nanoparticles (SeNPs), while examples 2 and 3 used 10 nm and 50 nm particles, respectively. Particle size can affect surface area and thus antioxidant activity. In example 1, an optimal balance between surface area and reactivity was achieved.
The molar ratios of EDC, sulfo-NHS and SenPs also varied during the step of linking the nanoparticles to the protein peptides. The 1:1:10 molar ratio used in example 1 is most advantageous for the formation of stable and active complexes. EDC (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide) and Sulfo-NHS (N-hydroxysulphonic acid sulfoxide) are used to activate carboxyl groups to form amide bonds, the molar ratio of these coupling agents being critical, the molar ratio having a direct effect on the efficiency of the reaction and on side reactions.
Comparative example 2: in this example, the protein peptide was added directly without conjugation to the nanoparticle. This explains its relatively low antioxidant activity.
Comparative example 5: as a commercial product, the raw materials and production process used are different from those of laboratory products, which are the reasons for the low antioxidant activity.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the invention are intended to be included within the scope of the invention.
Claims (10)
1. An antioxidant protein peptide-based nano hydrogel for burn wound surface, the preparation method comprises the following steps:
a) Covalent modification of selenium nanoparticles (SeNPs):
putting Senps into acetic acid buffer solution, stirring until the SeNPs are completely dispersed, adding silane coupling agent, continuously stirring, separating modified nano particles by using a centrifuge after the reaction is completed, washing the nano particles by using deionized water, and finally suspending the nano particles in the deionized water;
b) Linking the nanoparticle to the protein peptide:
uniformly mixing 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (Sulfo-NHS) with modified Senps, gradually adding protein peptide, continuously stirring the mixture, and centrifuging after the reaction is finished to obtain a protein peptide-nanoparticle compound;
c) Forming a first network:
uniformly mixing a Hyaluronic Acid (HA) solution and a protein peptide-nanoparticle compound, gradually adding sulfur dioxide, and stirring for reaction;
d) Forming a second network:
gradually adding PVA solution into the crosslinked HA network, stirring at high speed, adding boric acid solution into the mixture, and continuously stirring for reaction;
e) And (3) introducing an auxiliary agent:
tween 20 was added to the reaction product of d) to obtain a hydrogel.
2. The hydrogel of claim 1, wherein in step b), EDC: sulfo-NHS: the molar ratio of the SeNPs is (0.5-2): (8-12).
3. The gel of claim 1, wherein in step a), the silane coupling agent is used in an amount of 5 to 10% by weight of the nanoparticles.
4. The hydrogel of claim 1, wherein the SeNPs in step a) have a particle size of 10 to 50 nm.
5. The hydrogel of claim 1, wherein the amount of protein peptide added in step b) is 2-5% by weight of SeNPs.
6. The hydrogel according to claim 1, wherein the concentration of hyaluronic acid in step c) is in the range of 0.5-3% (w/v).
7. The hydrogel of claim 1, wherein in step d) the boric acid solution has a concentration in the range of 0.3-3% (w/v).
8. The hydrogel according to claim 1, wherein the sulfur dioxide used in step c) is added in an amount of 1-5% by weight of hyaluronic acid.
9. The hydrogel of claim 1, wherein the stirring reaction of step C) is carried out at 25 ℃ to 40 ℃.
10. The hydrogel according to claims 1 to 9, wherein Tween 20 is used in an amount of 0.1 to 1% of the total weight of the hydrogel in step e).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311198710.5A CN117138104A (en) | 2023-09-18 | 2023-09-18 | Antioxidant protein peptide-based nano hydrogel for burn wound surface |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311198710.5A CN117138104A (en) | 2023-09-18 | 2023-09-18 | Antioxidant protein peptide-based nano hydrogel for burn wound surface |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117138104A true CN117138104A (en) | 2023-12-01 |
Family
ID=88898790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311198710.5A Withdrawn CN117138104A (en) | 2023-09-18 | 2023-09-18 | Antioxidant protein peptide-based nano hydrogel for burn wound surface |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117138104A (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07102002A (en) * | 1993-09-30 | 1995-04-18 | Gunze Ltd | Cross-linked hyaluronic acid and compound material thereof |
CN102921015A (en) * | 2012-10-24 | 2013-02-13 | 江苏大学 | Hyaluronic acid nanometer selenium and preparation method as well as application thereof |
KR20150110843A (en) * | 2014-03-20 | 2015-10-05 | (주)진우바이오 | Preparing Method of Hyaluronic Acid Hydrogel by Physical Treatment |
TW201811376A (en) * | 2016-07-01 | 2018-04-01 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | Antibody-drug conjugates and therapeutic methods using the same |
CN110367544A (en) * | 2019-07-11 | 2019-10-25 | 广州大学 | A kind of nano granules of selenium and preparation method thereof based on polypeptide |
CN113383960A (en) * | 2021-06-10 | 2021-09-14 | 广州大学 | High-stability protein polypeptide-nano selenium and preparation method and application thereof |
CN116350615A (en) * | 2023-04-14 | 2023-06-30 | 天津理工大学 | Mitochondrion-targeted self-assembled seleno-peptide nanomaterial and preparation method and application thereof |
WO2023172363A1 (en) * | 2022-02-11 | 2023-09-14 | P&S Global Holdings Llc | Nanohybrid and nanocomposite compositions and methods for making and using same |
-
2023
- 2023-09-18 CN CN202311198710.5A patent/CN117138104A/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07102002A (en) * | 1993-09-30 | 1995-04-18 | Gunze Ltd | Cross-linked hyaluronic acid and compound material thereof |
CN102921015A (en) * | 2012-10-24 | 2013-02-13 | 江苏大学 | Hyaluronic acid nanometer selenium and preparation method as well as application thereof |
KR20150110843A (en) * | 2014-03-20 | 2015-10-05 | (주)진우바이오 | Preparing Method of Hyaluronic Acid Hydrogel by Physical Treatment |
TW201811376A (en) * | 2016-07-01 | 2018-04-01 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | Antibody-drug conjugates and therapeutic methods using the same |
CN110367544A (en) * | 2019-07-11 | 2019-10-25 | 广州大学 | A kind of nano granules of selenium and preparation method thereof based on polypeptide |
CN113383960A (en) * | 2021-06-10 | 2021-09-14 | 广州大学 | High-stability protein polypeptide-nano selenium and preparation method and application thereof |
WO2023172363A1 (en) * | 2022-02-11 | 2023-09-14 | P&S Global Holdings Llc | Nanohybrid and nanocomposite compositions and methods for making and using same |
CN116350615A (en) * | 2023-04-14 | 2023-06-30 | 天津理工大学 | Mitochondrion-targeted self-assembled seleno-peptide nanomaterial and preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
XU YANG: "Hyaluronic Acid-based injectable hydrogels for wound dressing and localized tumor therapy: A review", ADVANCED NANOBIOMED RESEARCH, vol. 2, no. 12, 26 October 2022 (2022-10-26), pages 2200124 * |
田廷璀: "透明质酸水凝胶制备的研究进展", 粘接, vol. 37, no. 5, 10 May 2016 (2016-05-10), pages 80 - 85 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5620706A (en) | Polyionic insoluble hydrogels comprising xanthan and chitosan | |
Dumitriu et al. | Polyionic hydrogels obtained by complexation between xanthan and chitosan: their properties as supports for enzyme immobilization | |
WO2019205749A1 (en) | Method for processing intelligent hydrogel using starch nanoparticles as skeleton | |
CN106177924A (en) | The preparation method of nanoscale lactoferrin chitosan particle | |
WO2009005709A1 (en) | Polypeptide microparticles | |
CN113575951B (en) | Starch-based dual-load functional nanoparticle, and preparation method and application thereof | |
CN114982958A (en) | Targeted modified astaxanthin-loaded cow milk exosome nano preparation and preparation method thereof | |
WO2009005718A1 (en) | Polypeptide microparticles having sustained release characteristics, methods and uses | |
Timpu et al. | Surface cationic functionalized nano-hydroxyapatite–Preparation, characterization, effect of coverage on properties and related applications | |
Guo et al. | Preparation and evaluation of pH-responsive charge-convertible ternary complex FA-PEI-CCA/PEI/DNA with low cytotoxicity and efficient gene delivery | |
CN103588998A (en) | Polysaccharide/PEI nanogel with reduction responsiveness, preparation, and preparation method of polysaccharide/PEI nanogel | |
Maire et al. | Retention of transforming growth factor β1 using functionalized dextran-based hydrogels | |
Chen et al. | Incorporation of Fmoc-Y nanofibers into Ca-alginate hydrogels for improving their mechanical properties and the controlled release of small molecules | |
CN101130575A (en) | Chitosan quaternary ammonium salt nano grain with hydrated sheath coating and method for preparing the same | |
KR102360781B1 (en) | Hydrocolloid Patch For Alleviating Skin Inflammation | |
CN117138104A (en) | Antioxidant protein peptide-based nano hydrogel for burn wound surface | |
CN112957515B (en) | Bioactive glass/thrombin composite hemostatic powder and preparation method and application thereof | |
Bae et al. | Gelation and the antioxidant and antibacterial properties of silk fibroin/tannic acid/Zn2+ mixtures | |
CN115025049B (en) | Hydrogel microsphere for efficiently loading anti-inflammatory drug and preparation method thereof | |
Su et al. | Controlled PEGylation of periodic mesoporous organosilica nanospheres for improving their stability in physiological solutions | |
CN114891239B (en) | Boron-nitrogen internal coordination borate hydrogel and preparation method thereof | |
CN113116857B (en) | Effervescent granule with adhesion function and application thereof | |
CN115536919A (en) | Modified chitosan adhesive hydrogel and preparation method and application thereof | |
CN113842374B (en) | Fucoidin-mesoporous silica composite nanoparticles for delivering curcumin | |
CN117159729B (en) | Porous stem cell-loaded biological material and application thereof in pain treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20231201 |